{
    "clinical_study": {
        "@rank": "70426", 
        "arm_group": {
            "arm_group_label": "teicoplanin", 
            "arm_group_type": "Experimental", 
            "description": "this group receive the teicoplanin"
        }, 
        "brief_summary": {
            "textblock": "This is a biomedical research, prospective, mono centric, tolerance study Of the\n      administration of subcutaneous teicoplanin in the treatment of osteoarticular infections."
        }, 
        "brief_title": "Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarticular Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient over 18 years\n\n          -  Inpatient orthopedic surgery\n\n          -  Achieved a bone and joint infection documented gram + (staphylococci golden\n             coagulase-negative staphylococci, enterococci, streptococci)\n\n          -  Bacteria resistant to lincosamides, quinolones and rifampicin\n\n          -  Bacteria susceptible to teicoplanin (MIC \u2264 4 mg / L)\n\n          -  Balanced patient teicoplanin administered intravenously (2 successive doses between\n             30 and 40 mg / mL)\n\n        Exclusion Criteria:\n\n          -  Patient not affiliated to the social security\n\n          -  Pregnant and lactating women\n\n          -  Known hypersensitivity to teicoplanin (rash, ...)\n\n          -  Patients with a central catheter or an implantable chamber\n\n          -  Patient hemodialysis\n\n          -  Patient has another participant biomedical research on a drug to prevent drug\n             interactions\n\n          -  Patient minor\n\n          -  Patient major protected (protection of the court, wardship, trusteeship)\n\n          -  Patient admitted for emergency or incapable of consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815541", 
            "org_study_id": "PI2012_843_0008", 
            "secondary_id": "2012-003690-25"
        }, 
        "intervention": {
            "arm_group_label": "teicoplanin", 
            "intervention_name": "teicoplanin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Teicoplanin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "subcutaneous teicoplanin", 
            "osteoarticular", 
            "infections", 
            "tolerance", 
            "teicoplanin"
        ], 
        "lastchanged_date": "March 19, 2013", 
        "location": {
            "contact": {
                "email": "elsamad.youssef@chu-amiens.fr", 
                "last_name": "Youssef EL SAMAD, PH", 
                "phone": "333 22 66 88 13"
            }, 
            "contact_backup": {
                "email": "aitamermeziane.mohamed@chu-amiens.fr", 
                "last_name": "Mohamed AIT AMER MEZIANE, CRA", 
                "phone": "03.22.66.80.60"
            }, 
            "facility": {
                "address": {
                    "city": "Amiens", 
                    "country": "France", 
                    "state": "Picardie", 
                    "zip": "80054"
                }, 
                "name": "CHU Amiens"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study", 
        "overall_contact": {
            "email": "elsamad.youssef@chu-amiens.fr", 
            "last_name": "Youssef El SAMAD, PH", 
            "phone": "00333 22 66 88 13"
        }, 
        "overall_official": {
            "affiliation": "CHU Amiens, France", 
            "last_name": "Youssef El SAMAD, PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of adverse reactions at the injection site SC will be measured to assess the local tolerance of teicoplanin by SC.", 
            "measure": "measure of tolerance", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815541"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Centre Hospitalier Universitaire, Amiens", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire, Amiens", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}